AUROBINDO PHARMA Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AUROBINDO PHARMA, and what generic and branded alternatives to AUROBINDO PHARMA drugs are available?
AUROBINDO PHARMA has four hundred and ninety-eight approved drugs.
There are nineteen tentative approvals on AUROBINDO PHARMA drugs.
Summary for AUROBINDO PHARMA
| US Patents: | 0 |
| Tradenames: | 384 |
| Ingredients: | 357 |
| NDAs: | 498 |
| Patent Litigation for AUROBINDO PHARMA: | See patent lawsuits for AUROBINDO PHARMA |
| PTAB Cases with AUROBINDO PHARMA as petitioner: | See PTAB cases with AUROBINDO PHARMA as petitioner |
Drugs and US Patents for AUROBINDO PHARMA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aurobindo Pharma Ltd | LAMIVUDINE | lamivudine | TABLET;ORAL | 202032-002 | Nov 17, 2011 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Aurobindo Pharma | ZOLPIDEM TARTRATE | zolpidem tartrate | TABLET;ORAL | 078413-002 | May 4, 2007 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Aurobindo Pharma Ltd | PREDNISONE | prednisone | TABLET;ORAL | 215672-004 | Mar 28, 2022 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for AUROBINDO PHARMA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Aurobindo Pharma Usa | MAXZIDE | hydrochlorothiazide; triamterene | TABLET;ORAL | 019129-001 | Oct 22, 1984 | 4,105,783 | ⤷ Subscribe |
| Aurobindo Pharma Usa | MAXZIDE | hydrochlorothiazide; triamterene | TABLET;ORAL | 019129-001 | Oct 22, 1984 | 4,444,769 | ⤷ Subscribe |
| Aurobindo Pharma Usa | MAXZIDE-25 | hydrochlorothiazide; triamterene | TABLET;ORAL | 019129-003 | May 13, 1988 | 4,444,769 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for AUROBINDO PHARMA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
